Clik here to view.
Cyclo Therapeutics to Present at the China NPC Association Meeting
GAINESVILLE, Fla. Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through...
View ArticleClik here to view.
2022 International Symposium on Human Identification (ISHI) Keynote DeNeen L....
MADISON, Wis. More than 1000 forensic DNA experts and law enforcement professionals from around the world will gather at the International Symposium on Human Identification (ISHI) October 31 –...
View ArticleClik here to view.
Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients...
SOUTH SAN FRANCISCO, Calif. Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-203A...
View ArticleClik here to view.
EpiAxis Therapeutics ＆ Peptilogics Enter Strategic Drug Discovery Partnership
SYDNEY & PITTSBURGH EpiAxis Therapeutics, a leading epigenetics company with a focus on the treatment, diagnosis and monitoring of cancer and the prevention of its recurrence, and Peptilogics, a...
View ArticleClik here to view.
Pillar Biosciences Receives China National Medical Products Administration...
NATICK, Mass. Pillar Biosciences, the leader in Decision Medicine™, developers and distributors of next-generation sequencing (NGS) tests which localize testing and reduce time to treatment...
View ArticleClik here to view.
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and...
View ArticleClik here to view.
CANbridge Announces Financial Results and Corporate Updates for Six Months...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (“CANbridge,” 1228.HK), a China and U.S.-based global biopharmaceutical company committed to the research, development and...
View ArticleClik here to view.
Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View ArticleClik here to view.
GICELL Announces Research Collaboration with HK inno.N for next-generation...
SEOUL, South Korea GICELL announced research and development collaboration for allogeneic CAR-NK candidates with HK inno.N on August 29th, 2022. This press release features multimedia. View the full...
View ArticleClik here to view.
Genome Insight and Ajou University Medical Center Launch Program to Apply...
SAN DIEGO Genome Insight, a cancer whole genome platform company, is launching a pilot program in Ajou University Medical Center to test the use of Whole Genome Sequencing (WGS) in routine cancer...
View ArticleClik here to view.
Anuva Announces Series A Closure and Enters Into a Strategic Partnership With...
MUMBAI, India Anuva (formerly known as Global Gene Corp) enters into its next stage of growth focused on creating the most diverse Genomic Bio / Data Bank at scale. To enable this, Anuva is entering...
View ArticleClik here to view.
Cerebras Systems Enables GPU-Impossible™ Long Sequence Lengths Improving...
SUNNYVALE, Calif. Cerebras Systems, the pioneer in accelerating artificial intelligence (AI) compute, released yet another industry-first capability today. Customers can now rapidly train...
View ArticleClik here to view.
GenBody America Receives Amendment to FDA Emergency Use Authorization for...
JURUPA VALLEY, Calif. GenBody America, LLC, the U.S. affiliate of GenBody, Inc., a South Korean manufacturer of rapid diagnostic tests and reagents for point-of-care applications for COVID-19, today...
View ArticleClik here to view.
Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles...
BRISTOL, N.J. & SEOUL Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it...
View ArticleClik here to view.
Prolific Machinesがトップクラスのプラネタリーヘルス投資家から4200万ドルを調達し、生物学組立ラインを構築へ
サンフランシスコ （ビジネスワイヤ） — 次世代バイオテクノロジー企業のProlific...
View ArticleClik here to view.
Prolific Machines从顶级的星球健康投资人筹集了4,200万美元，用于建立生物学生产线
旧金山 (美国商业资讯)–新一代生物技术公司Prolific Machines今天走出隐身模式，宣布其种子轮和A轮融资实现大幅超额认购。两轮融资均由该领域一流的风险投资人领投。种子轮融资由人造肉的首位投资人、梅菲尔德风险投资公司(Mayfield)的Arvind Gupta领投。A轮融资由比尔·盖茨创立的Breakthrough Energy...
View ArticleClik here to view.
BostonGene Showcases Lifesaving Cancer Diagnostic and Treatment...
WALTHAM, Mass. BostonGene announced today that it will participate in the 81st Annual Meeting of the Japanese Cancer Association. The event, to be held at Pacific Convention Plaza Yokohama from...
View ArticleClik here to view.
ネルビアーノ・メディカル・サイエンシズがメルクとの提携およびライセンスオプション契約を発表
伊ネルビアーノ （ビジネスワイヤ） — NMSグループの一員であり、革新的ながん治療薬の創薬と開発を手掛ける臨床段階の企業であるネルビアーノ・メディカル・サイエンシズ（NMS）は本日、高度に選択的で脳透過性がある次世代PARP1阻害剤NMS-293に関するライセンスオプション付きの提携契約をメルク・ヘルスケア（メルク）と締結したと発表しました。...
View ArticleClik here to view.
Nerviano Medical Sciences S.r.l.宣布与默克达成包含许可选择权的合作协议
意大利内尔维亚诺 (美国商业资讯)–Nerviano Medical Sciences S.r.l. (NMS)是NMS集团下属成员公司，也是一家发现和开发癌症创新疗法的临床阶段公司。该公司今天宣布与Merck Healthcare KGaA签署了一项包含许可选择权的合作协议，以开发新一代高选择性和脑渗透性PARP1抑制剂NMS-293。...
View ArticleClik here to view.
NewAmsterdam Pharma Announces Initiation of Phase 2 Dose-Finding Study...
NAARDEN, Netherlands & MIAMI NewAmsterdam Pharma, a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced that...
View Article